Lumida
/ABEO
⌘K
Abeona Therapeutics Inc

Abeona Therapeutics Inc

ABEO
$6.06USD-0.49%-0.03 today

MARKET CAP

346.5M

P/E (TTM)

6.2x

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$4
$8

AI Summary

Stalk
StalkMedium

In a Stage 2 advance with clear higher highs and higher lows, price has broken above a key pivot but is currently extended and overbought. Speculative engagement should be deferred until a pullback into the rising EMA 9/21/50 cluster confirms support.

  • Q1 2026 revenue jumped 262% QoQ to $8.7 M on initial ZivaSkin treatments
  • CMS granted NTAP status for ZivaSkin, improving reimbursement rates
  • Q1 2026 net loss was $17.1 M with SG&A up to $19.5 M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022FY 2023FY 2025TREND
Sales, Adj.$10.0M$3.0M$1.4M$3.5M$5.8M
YoY %-70.0%-52.9%+147.5%
P / Sales14.5x11.1x15.9x33.8x59.9x
EV / Sales18.2x12.5x32.3x43.7x56.8x
Gross Profit, Adj.$10.0M$3.0M$1.4M$3.5M$4.3M
YoY %-70.0%-52.9%+147.5%
Margin %100.0%100.0%100.0%100.0%73.7%
EV / Gross Profit18.2x12.5x32.3x43.7x77.1x
EBITDA, Adj.$-42.9M$-52.9M$-43.2M$-44.8M$-86.9M
YoY %+38.1%-23.3%+18.3%-3.8%-39.7%
Margin %-429.0%-1763.0%-3054.5%-1281.3%-1493.1%
EV / EBITDA-4.2x-0.7x-1.1x-3.4x-3.8x
EBIT$-81.4M$-89.8M$-50.9M$-47.1M$-89.4M
YoY %-5.6%-10.3%+43.3%+7.4%-39.3%
Margin %-814.2%-2994.0%-3600.8%-1346.7%-1536.9%
EV / EBIT-2.2x-0.4x-0.9x-3.2x-3.7x
Net Income$-84.2M$-84.9M$-43.5M$-54.2M$71.2M
YoY %-10.4%-0.8%+48.8%-24.6%+211.7%
Net Margin-842.3%-2831.2%-3074.8%-1548.2%1223.1%
EPS (GAAP)-$22.75-$21.57-$5.53-$2.53$1.01
YoY %+39.7%+5.2%+74.4%+54.2%+165.2%